



## New Trends in Vaccine Characterization, Formulations, and Development

Guest Editor:

**Dr. Ravinder Kumar**

Department of Biological  
Sciences, Rensselaer Polytechnic  
Institute, Troy, NY 12180, USA

Deadline for manuscript  
submissions:

**closed (20 February 2024)**

### Message from the Guest Editor

Over the last few decades, several platforms have been used for vaccine development, formulation, and delivery. Each platform its own unique advantages over other platforms. This has led to the availability of different types of vaccines ranging from conventional attenuated or killed whole pathogen to subunit vaccines and, nucleic acid-based vaccines such as mRNA-based vaccines. Even though modern vaccines are proven to be safe and effective, they still suffer from numerous limitations such as poor thermostability, short shelf life at room temperature, and the requirement for specialized needles and syringes. To overcome these issues, new formulations and modes of vaccine delivery are currently under investigation.

We would like to encourage submissions on recent advances made in vaccine characterization, formulation, and development, for which original research articles, reviews, communications, case reports, and clinical trials mentioning technological improvements in the field of vaccines are welcome. Papers describing novel formulations, the development of new platforms for vaccine delivery, identification of novel adjuvants, and novel modes of delivery are also welcome.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)